Innovent to seek $400M-plus on Hong Kong IPO, reports say; will it revive biotech's fortunes on HKEX?
With a clear goal to lead the first biosimilar wave in China while giving a go at new drug innovation, Innovent Biologics has been raising …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
